[Therapeutic Efficacy of Multigly-Cosidorum Tripterygium Combined with rhIL-11 for Immune Thrombocytopenia].

Abstract

OBJECTIVE:

To study the therapeutic efficacy of multigly-cosidorum Tripterygium combined with rhIL-11 for treating patients with immune thrombocytopenia (ITP).

METHODS:

A total of 75 patients with ITP were divided into 2 group: experimental group and control group. The experimental group included 40 patients who had been treated with multigly-cosidorum Tripterygium combined with rhIL-11. Multigly-cosidorum Tripterygium was given at a dose of 1mg/kg·d for 2 months and rhIL-11 was injected at a dose of 16,000,000 units per day. Control group included 35 patients who had been treated with prednisone at a dose of 1 mg/kg·d. Platelet counts were performed every day before platelet counts >30 × 10⁹/L. Peripheral blood T cells were collected before and after treated for 2 months. The ratios of CD4⁺, CD8⁺ T cells in peripheral blood T cells were analyzed by flow cytometry.

RESULTS:

Totally effective rate in experimental group was 77.5%. Totally effective rate in control group was 82.9%. Totally effective rate showed no statistical difference between these two groups (P > 0.05). The average time of platelet count 30 × 10⁹/L in experimental and control groups were 13.06 ± 6.10 days and 9.76 ± 5.71 days respectively; in experimental group, the ratio of CD4⁺ T cells in peripheral blood was 21.03% before treatment, then rised to 34.49% after treatment for 2 months (P < 0.01); The ratio of CD8⁺ T cells in peripheral blood was 26.35% before treatment, then decreased to 20.18% (P < 0.01). In control group, the ratio of CD4⁺ T cells was 22.30% before treatment, then rised to 25.11% after treatment for 2 months (P < 0.05); The ratio of CD8⁺ T cells in peripheral blood was 27.24% before treatment, then decreased to 21.35% (P < 0.01).

CONCLUSION:

Multigly-cosidorum tripterygium can correct disorder of T lymphocytes, the combination of multigly-cosidorum triptergium and rhIL-11 can accelerate therapeutic efficacy for treating ITP and with less adverse reaction, so this combination may be effective and safe for treating patients with ITP.

• Authors: Xian-Qiu Yu, Hong-Mei Chen, Jin-Hua Sun, Ming Luo, Yi-Long Lu
• Journal: Zhongguo shi yan xue ye xue za zhi (Zhongguo Shi Yan Xue Ye Xue Za Zhi) Vol. 23 Issue 5 Pg. 1400-3 (Oct 2015) ISSN: 1009-2137 [Print] China
• PMID: 26524046 (Publication Type: Controlled Clinical Trial, Journal Article)

Chemical References

• Antineoplastic Agents
• Drugs, Chinese Herbal
• Interleukin-11
• Recombinant Proteins
• oprelvekin

Topics

• Antineoplastic Agents (therapeutic use)
• Drugs, Chinese Herbal (therapeutic use)
• Humans
• Interleukin-11 (therapeutic use)
• Platelet Count
• Purpura, Thrombocytopenic, Idiopathic (drug therapy)
• Recombinant Proteins (therapeutic use)
• T-Lymphocytes
• Tripterygium (chemistry)